<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2025//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_250101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">3264384</PMID><DateCompleted><Year>1989</Year><Month>01</Month><Day>23</Day></DateCompleted><DateRevised><Year>2021</Year><Month>01</Month><Day>03</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0028-4793</ISSN><JournalIssue CitedMedium="Print"><Volume>319</Volume><Issue>25</Issue><PubDate><Year>1988</Year><Month>Dec</Month><Day>22</Day></PubDate></JournalIssue><Title>The New England journal of medicine</Title><ISOAbbreviation>N Engl J Med</ISOAbbreviation></Journal><ArticleTitle>Use of tumor-infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma. A preliminary report.</ArticleTitle><Pagination><StartPage>1676</StartPage><EndPage>1680</EndPage><MedlinePgn>1676-80</MedlinePgn></Pagination><Abstract><AbstractText>Lymphocytes extracted from freshly resected melanomas can be expanded in vitro and can often mediate specific lysis of autologous tumor cells but not allogeneic tumor or autologous normal cells. We treated 20 patients with metastatic melanoma by means of adoptive transfer of these tumor-infiltrating lymphocytes and interleukin-2, after the patients had received a single intravenous dose of cyclophosphamide. Objective regression of the cancer was observed in 9 of 15 patients (60 percent) who had not previously been treated with interleukin-2 and in 2 of 5 patients (40 percent) in whom previous therapy with interleukin-2 had failed. Regression of cancer occurred in the lungs, liver, bone, skin, and subcutaneous sites and lasted from 2 to more than 13 months. Toxic effects of interleukin-2 occurred, although the treatment course was short (five days); these side effects were reversible. It appears that in patients with metastatic melanoma, this experimental treatment regimen can produce higher response rates than those achieved with interleukin-2 administered alone or with lymphokine-activated killer cells. It is too early to determine whether this new form of immunotherapy can improve survival, but further trials seem warranted.</AbstractText></Abstract><AuthorList CompleteYN="N"><Author ValidYN="Y"><LastName>Rosenberg</LastName><ForeName>S A</ForeName><Initials>SA</Initials><AffiliationInfo><Affiliation>Surgery Branch, National Cancer Institute, Bethesda, MD 20892.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Packard</LastName><ForeName>B S</ForeName><Initials>BS</Initials></Author><Author ValidYN="Y"><LastName>Aebersold</LastName><ForeName>P M</ForeName><Initials>PM</Initials></Author><Author ValidYN="Y"><LastName>Solomon</LastName><ForeName>D</ForeName><Initials>D</Initials></Author><Author ValidYN="Y"><LastName>Topalian</LastName><ForeName>S L</ForeName><Initials>SL</Initials></Author><Author ValidYN="Y"><LastName>Toy</LastName><ForeName>S T</ForeName><Initials>ST</Initials></Author><Author ValidYN="Y"><LastName>Simon</LastName><ForeName>P</ForeName><Initials>P</Initials></Author><Author ValidYN="Y"><LastName>Lotze</LastName><ForeName>M T</ForeName><Initials>MT</Initials></Author><Author ValidYN="Y"><LastName>Yang</LastName><ForeName>J C</ForeName><Initials>JC</Initials></Author><Author ValidYN="Y"><LastName>Seipp</LastName><ForeName>C A</ForeName><Initials>CA</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>N Engl J Med</MedlineTA><NlmUniqueID>0255562</NlmUniqueID><ISSNLinking>0028-4793</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007376">Interleukin-2</NameOfSubstance></Chemical><Chemical><RegistryNumber>8N3DW7272P</RegistryNumber><NameOfSubstance UI="D003520">Cyclophosphamide</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>N Engl J Med. 1989 May 25;320(21):1418-9. doi: 10.1056/NEJM198905253202115.</RefSource><PMID Version="1">2785641</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002478" MajorTopicYN="N">Cells, Cultured</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003131" MajorTopicYN="N">Combined Modality Therapy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003520" MajorTopicYN="N">Cyclophosphamide</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007167" MajorTopicYN="N">Immunotherapy</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007376" MajorTopicYN="N">Interleukin-2</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="Y">administration &amp; dosage</QualifierName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008214" MajorTopicYN="N">Lymphocytes</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008545" MajorTopicYN="N">Melanoma</DescriptorName><QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009362" MajorTopicYN="N">Neoplasm Metastasis</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>1988</Year><Month>12</Month><Day>22</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>1988</Year><Month>12</Month><Day>22</Day><Hour>0</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>1988</Year><Month>12</Month><Day>22</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">3264384</ArticleId><ArticleId IdType="doi">10.1056/NEJM198812223192527</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">3265581</PMID><DateCompleted><Year>1989</Year><Month>03</Month><Day>22</Day></DateCompleted><DateRevised><Year>2019</Year><Month>06</Month><Day>22</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0065-2598</ISSN><JournalIssue CitedMedium="Print"><Volume>233</Volume><PubDate><Year>1988</Year></PubDate></JournalIssue><Title>Advances in experimental medicine and biology</Title><ISOAbbreviation>Adv Exp Med Biol</ISOAbbreviation></Journal><ArticleTitle>Current approaches to the adoptive immunotherapy of cancer.</ArticleTitle><Pagination><StartPage>459</StartPage><EndPage>467</EndPage><MedlinePgn>459-67</MedlinePgn></Pagination><Abstract><AbstractText>Interleukin 2 has provided the means of generating activated lymphocytes from the tumor-bearing host which show in vitro anti-tumor activity. These cells can be derived either from a ubiquitous null cell precursor population, exhibiting promiscuous lysis of nearly all tumors after culture in IL2 (ie. the LAK cell) or from a T cell precursor population infiltrating tumors and showing some relative specificity for lysis of the autologous tumor following activation (ie. TIL). When utilized in murine cellular adoptive immunotherapy models, both LAK cells and TIL are able to display marked anti-tumor effects against established micrometastatic tumor. LAK cells have been subsequently employed in adoptive immunotherapy against metastatic human tumors and in a limited number of cases have been able to mediate the regression of advanced cancers of differing histologies. The role of adoptive immunotherapy as standard therapy of human tumors will depend on refinement of the methodology and progress toward increased efficacy and reduced toxicity. TIL may possess theoretical advantages in these areas and efforts are currently proceeding to evaluate these new anti-tumor reagents in the the treatment of patients with cancer.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Yang</LastName><ForeName>J C</ForeName><Initials>JC</Initials><AffiliationInfo><Affiliation>Surgery Branch, National Cancer Institute Bethesda, Md.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rosenberg</LastName><ForeName>S A</ForeName><Initials>SA</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Adv Exp Med Biol</MedlineTA><NlmUniqueID>0121103</NlmUniqueID><ISSNLinking>0065-2598</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007376">Interleukin-2</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003602" MajorTopicYN="N">Cytotoxicity, Immunologic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007116" MajorTopicYN="Y">Immunization, Passive</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007376" MajorTopicYN="N">Interleukin-2</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007694" MajorTopicYN="N">Killer Cells, Natural</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008113" MajorTopicYN="N">Liver Neoplasms</DescriptorName><QualifierName UI="Q000556" MajorTopicYN="N">secondary</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008175" MajorTopicYN="N">Lung Neoplasms</DescriptorName><QualifierName UI="Q000556" MajorTopicYN="N">secondary</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008213" MajorTopicYN="N">Lymphocyte Activation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008545" MajorTopicYN="N">Melanoma</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009362" MajorTopicYN="N">Neoplasm Metastasis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009374" MajorTopicYN="N">Neoplasms, Experimental</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName><QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>1988</Year><Month>1</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>1988</Year><Month>1</Month><Day>1</Day><Hour>0</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>1988</Year><Month>1</Month><Day>1</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">3265581</ArticleId><ArticleId IdType="doi">10.1007/978-1-4899-5037-6_50</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">3041925</PMID><DateCompleted><Year>1988</Year><Month>09</Month><Day>08</Day></DateCompleted><DateRevised><Year>2019</Year><Month>05</Month><Day>14</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0003-4932</ISSN><JournalIssue CitedMedium="Print"><Volume>208</Volume><Issue>2</Issue><PubDate><Year>1988</Year><Month>Aug</Month></PubDate></JournalIssue><Title>Annals of surgery</Title><ISOAbbreviation>Ann Surg</ISOAbbreviation></Journal><ArticleTitle>The development of new immunotherapies for the treatment of cancer using interleukin-2. A review.</ArticleTitle><Pagination><StartPage>121</StartPage><EndPage>135</EndPage><MedlinePgn>121-35</MedlinePgn></Pagination><Abstract><AbstractText>Recent increases in knowledge of cellular immunology, combined with developments in biotechnology, have provided new opportunities for the development of immunotherapies for the treatment of cancer in humans. One approach to therapy is that of adoptive immunotherapy, that is, the transfer to the tumor bearing host of lymphoid cells with antitumor reactivity that can mediate antitumor responses. Several lymphocyte subpopulations have now been identified that may be suitable for use in adoptive immunotherapy. Resting lymphocytes incubated in interleukin-2 (IL-2) give rise to lymphokine activated killer (LAK) cells that can lyse malignant cells, but not normal cells. Clinical studies in patients with advanced cancer have revealed that treatment with high dose IL-2 alone or in combination with LAK cells can mediate the complete or partial regression of cancer in selected patients. Other approaches are currently undergoing investigation, including the adoptive transfer of tumor infiltrating lymphocytes, which, in animal models, have antitumor reactivity 50-100 times more potent than do LAK cells. Other new approaches to immunotherapy include the use of combination of lymphokines, such as the use of tumor necrosis factor or alpha interferon in conjunction with IL-2. The availability of recombinant lymphokines that provide large amounts of biologically active materials can hopefully lead to the development of effective new therapies for cancer in humans.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Rosenberg</LastName><ForeName>S A</ForeName><Initials>SA</Initials><AffiliationInfo><Affiliation>Surgery Branch, National Cancer Institute, Bethesda, MD 20014.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Ann Surg</MedlineTA><NlmUniqueID>0372354</NlmUniqueID><ISSNLinking>0003-4932</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007370">Interferon Type I</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007376">Interleukin-2</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D008222">Lymphokines</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014409">Tumor Necrosis Factor-alpha</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007116" MajorTopicYN="N">Immunization, Passive</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007167" MajorTopicYN="N">Immunotherapy</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007370" MajorTopicYN="N">Interferon Type I</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007376" MajorTopicYN="N">Interleukin-2</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007694" MajorTopicYN="N">Killer Cells, Natural</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008214" MajorTopicYN="N">Lymphocytes</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008222" MajorTopicYN="N">Lymphokines</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009369" MajorTopicYN="N">Neoplasms</DescriptorName><QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009374" MajorTopicYN="N">Neoplasms, Experimental</DescriptorName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014409" MajorTopicYN="N">Tumor Necrosis Factor-alpha</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>1988</Year><Month>8</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>1988</Year><Month>8</Month><Day>1</Day><Hour>0</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>1988</Year><Month>8</Month><Day>1</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>1989</Year><Month>2</Month><Day>1</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">3041925</ArticleId><ArticleId IdType="pmc">PMC1493624</ArticleId><ArticleId IdType="doi">10.1097/00000658-198808000-00001</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Nature. 1978 Jul 20;274(5668):269-71</Citation><ArticleIdList><ArticleId IdType="pubmed">308186</ArticleId></ArticleIdList></Reference><Reference><Citation>J Immunol. 1980 Jul;125(1):238-45</Citation><ArticleIdList><ArticleId IdType="pubmed">6966652</ArticleId></ArticleIdList></Reference><Reference><Citation>J Immunol. 1980 Oct;125(4):1487-93</Citation><ArticleIdList><ArticleId IdType="pubmed">6967906</ArticleId></ArticleIdList></Reference><Reference><Citation>J Immunol. 1981 Jul;127(1):266-71</Citation><ArticleIdList><ArticleId IdType="pubmed">7195411</ArticleId></ArticleIdList></Reference><Reference><Citation>Cancer Res. 1981 Nov;41(11 Pt 1):4420-5</Citation><ArticleIdList><ArticleId IdType="pubmed">6975652</ArticleId></ArticleIdList></Reference><Reference><Citation>Cancer Res. 1982 Mar;42(3):913-8</Citation><ArticleIdList><ArticleId IdType="pubmed">7059990</ArticleId></ArticleIdList></Reference><Reference><Citation>J Exp Med. 1982 Jun 1;155(6):1823-41</Citation><ArticleIdList><ArticleId IdType="pubmed">6176669</ArticleId></ArticleIdList></Reference><Reference><Citation>J Immunol. 1983 Feb;130(2):958-64</Citation><ArticleIdList><ArticleId IdType="pubmed">6848602</ArticleId></ArticleIdList></Reference><Reference><Citation>J Exp Med. 1983 Mar 1;157(3):884-97</Citation><ArticleIdList><ArticleId IdType="pubmed">6601174</ArticleId></ArticleIdList></Reference><Reference><Citation>Nature. 1983 Mar 24-30;302(5906):305-10</Citation><ArticleIdList><ArticleId IdType="pubmed">6403867</ArticleId></ArticleIdList></Reference><Reference><Citation>Cancer Immunol Immunother. 1983;15(1):1-10</Citation><ArticleIdList><ArticleId IdType="pubmed">6603260</ArticleId></ArticleIdList></Reference><Reference><Citation>Cancer Res. 1983 Dec;43(12 Pt 1):5729-34</Citation><ArticleIdList><ArticleId IdType="pubmed">6640524</ArticleId></ArticleIdList></Reference><Reference><Citation>Cancer. 1984 Feb 15;53(4):896-905</Citation><ArticleIdList><ArticleId IdType="pubmed">6692292</ArticleId></ArticleIdList></Reference><Reference><Citation>Cancer Treat Rep. 1984 Jan;68(1):233-55</Citation><ArticleIdList><ArticleId IdType="pubmed">6362866</ArticleId></ArticleIdList></Reference><Reference><Citation>J Exp Med. 1984 Feb 1;159(2):495-507</Citation><ArticleIdList><ArticleId IdType="pubmed">6141211</ArticleId></ArticleIdList></Reference><Reference><Citation>J Immunol. 1984 Apr;132(4):2123-8</Citation><ArticleIdList><ArticleId IdType="pubmed">6607956</ArticleId></ArticleIdList></Reference><Reference><Citation>Science. 1984 Mar 30;223(4643):1412-4</Citation><ArticleIdList><ArticleId IdType="pubmed">6367046</ArticleId></ArticleIdList></Reference><Reference><Citation>Cancer Res. 1984 May;44(5):1946-53</Citation><ArticleIdList><ArticleId IdType="pubmed">6608989</ArticleId></ArticleIdList></Reference><Reference><Citation>Science. 1984 Sep 28;225(4669):1487-9</Citation><ArticleIdList><ArticleId IdType="pubmed">6332379</ArticleId></ArticleIdList></Reference><Reference><Citation>J Immunol. 1985 Jan;134(1):157-66</Citation><ArticleIdList><ArticleId IdType="pubmed">3871099</ArticleId></ArticleIdList></Reference><Reference><Citation>J Biol Response Mod. 1984 Oct;3(5):501-11</Citation><ArticleIdList><ArticleId IdType="pubmed">6389777</ArticleId></ArticleIdList></Reference><Reference><Citation>Cancer. 1985 Mar 15;55(6):1327-33</Citation><ArticleIdList><ArticleId IdType="pubmed">3871657</ArticleId></ArticleIdList></Reference><Reference><Citation>J Exp Med. 1985 May 1;161(5):1169-88</Citation><ArticleIdList><ArticleId IdType="pubmed">3886826</ArticleId></ArticleIdList></Reference><Reference><Citation>J Immunol. 1985 Jul;135(1):646-52</Citation><ArticleIdList><ArticleId IdType="pubmed">3889158</ArticleId></ArticleIdList></Reference><Reference><Citation>J Immunol. 1985 Aug;135(2):1488-97</Citation><ArticleIdList><ArticleId IdType="pubmed">3891854</ArticleId></ArticleIdList></Reference><Reference><Citation>Cancer Res. 1985 Aug;45(8):3735-41</Citation><ArticleIdList><ArticleId IdType="pubmed">3893689</ArticleId></ArticleIdList></Reference><Reference><Citation>J Immunol. 1985 Oct;135(4):2865-75</Citation><ArticleIdList><ArticleId IdType="pubmed">2993418</ArticleId></ArticleIdList></Reference><Reference><Citation>J Immunol. 1985 Nov;135(5):3623-35</Citation><ArticleIdList><ArticleId IdType="pubmed">3900213</ArticleId></ArticleIdList></Reference><Reference><Citation>N Engl J Med. 1985 Dec 5;313(23):1485-92</Citation><ArticleIdList><ArticleId IdType="pubmed">3903508</ArticleId></ArticleIdList></Reference><Reference><Citation>J Immunol. 1985 Dec;135(6):4273-80</Citation><ArticleIdList><ArticleId IdType="pubmed">3877766</ArticleId></ArticleIdList></Reference><Reference><Citation>Cancer Res. 1986 Feb;46(2):676-83</Citation><ArticleIdList><ArticleId IdType="pubmed">3484431</ArticleId></ArticleIdList></Reference><Reference><Citation>Clin Immunol Immunopathol. 1986 Mar;38(3):367-80</Citation><ArticleIdList><ArticleId IdType="pubmed">3080265</ArticleId></ArticleIdList></Reference><Reference><Citation>Cancer Res. 1986 Jun;46(6):3011-7</Citation><ArticleIdList><ArticleId IdType="pubmed">3486040</ArticleId></ArticleIdList></Reference><Reference><Citation>J Immunol. 1986 May 15;136(10):3891-8</Citation><ArticleIdList><ArticleId IdType="pubmed">3486223</ArticleId></ArticleIdList></Reference><Reference><Citation>J Immunol. 1986 May 15;136(10):3899-909</Citation><ArticleIdList><ArticleId IdType="pubmed">2871106</ArticleId></ArticleIdList></Reference><Reference><Citation>J Immunol. 1986 Sep 1;137(5):1735-42</Citation><ArticleIdList><ArticleId IdType="pubmed">3528289</ArticleId></ArticleIdList></Reference><Reference><Citation>Science. 1986 Sep 19;233(4770):1318-21</Citation><ArticleIdList><ArticleId IdType="pubmed">3489291</ArticleId></ArticleIdList></Reference><Reference><Citation>Cancer Res. 1986 Nov;46(11):5618-23</Citation><ArticleIdList><ArticleId IdType="pubmed">3489525</ArticleId></ArticleIdList></Reference><Reference><Citation>Cancer Res. 1986 Nov;46(11):5633-40</Citation><ArticleIdList><ArticleId IdType="pubmed">3489526</ArticleId></ArticleIdList></Reference><Reference><Citation>JAMA. 1986 Dec 12;256(22):3117-24</Citation><ArticleIdList><ArticleId IdType="pubmed">3491225</ArticleId></ArticleIdList></Reference><Reference><Citation>J Immunol. 1987 Feb 1;138(3):989-95</Citation><ArticleIdList><ArticleId IdType="pubmed">3100623</ArticleId></ArticleIdList></Reference><Reference><Citation>Cell Immunol. 1987 Feb;104(2):366-76</Citation><ArticleIdList><ArticleId IdType="pubmed">3493081</ArticleId></ArticleIdList></Reference><Reference><Citation>J Immunol. 1987 Mar 15;138(6):1992-8</Citation><ArticleIdList><ArticleId IdType="pubmed">3493293</ArticleId></ArticleIdList></Reference><Reference><Citation>J Clin Oncol. 1987 Mar;5(3):496-503</Citation><ArticleIdList><ArticleId IdType="pubmed">3493332</ArticleId></ArticleIdList></Reference><Reference><Citation>N Engl J Med. 1987 Apr 9;316(15):889-97</Citation><ArticleIdList><ArticleId IdType="pubmed">3493432</ArticleId></ArticleIdList></Reference><Reference><Citation>N Engl J Med. 1987 Apr 9;316(15):898-905</Citation><ArticleIdList><ArticleId IdType="pubmed">3493433</ArticleId></ArticleIdList></Reference><Reference><Citation>Cancer Res. 1987 Jun 1;47(11):2771-6</Citation><ArticleIdList><ArticleId IdType="pubmed">3494504</ArticleId></ArticleIdList></Reference><Reference><Citation>Ann Intern Med. 1987 Jun;106(6):817-22</Citation><ArticleIdList><ArticleId IdType="pubmed">3495213</ArticleId></ArticleIdList></Reference><Reference><Citation>Blood. 1987 Jun;69(6):1654-60</Citation><ArticleIdList><ArticleId IdType="pubmed">3495302</ArticleId></ArticleIdList></Reference><Reference><Citation>J Immunol. 1987 Jul 1;139(1):285-94</Citation><ArticleIdList><ArticleId IdType="pubmed">3108401</ArticleId></ArticleIdList></Reference><Reference><Citation>J Immunol. 1987 Jul 1;139(1):295-304</Citation><ArticleIdList><ArticleId IdType="pubmed">2953816</ArticleId></ArticleIdList></Reference><Reference><Citation>Cancer Res. 1987 Aug 15;47(16):4366-71</Citation><ArticleIdList><ArticleId IdType="pubmed">3111684</ArticleId></ArticleIdList></Reference><Reference><Citation>Ann Intern Med. 1987 Sep;107(3):293-300</Citation><ArticleIdList><ArticleId IdType="pubmed">3497595</ArticleId></ArticleIdList></Reference><Reference><Citation>J Immunol Methods. 1987 Aug 24;102(1):127-41</Citation><ArticleIdList><ArticleId IdType="pubmed">3305708</ArticleId></ArticleIdList></Reference><Reference><Citation>Cancer Res. 1988 Jan 1;48(1):122-9</Citation><ArticleIdList><ArticleId IdType="pubmed">3257159</ArticleId></ArticleIdList></Reference><Reference><Citation>Cancer Res. 1988 Jan 1;48(1):206-14</Citation><ArticleIdList><ArticleId IdType="pubmed">3257161</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">3493432</PMID><DateCompleted><Year>1987</Year><Month>04</Month><Day>23</Day></DateCompleted><DateRevised><Year>2021</Year><Month>01</Month><Day>03</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0028-4793</ISSN><JournalIssue CitedMedium="Print"><Volume>316</Volume><Issue>15</Issue><PubDate><Year>1987</Year><Month>Apr</Month><Day>09</Day></PubDate></JournalIssue><Title>The New England journal of medicine</Title><ISOAbbreviation>N Engl J Med</ISOAbbreviation></Journal><ArticleTitle>A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high-dose interleukin-2 alone.</ArticleTitle><Pagination><StartPage>889</StartPage><EndPage>897</EndPage><MedlinePgn>889-97</MedlinePgn></Pagination><Abstract><AbstractText>We studied the effects of adoptive immunotherapy with lymphokine-activated killer (LAK) cells plus interleukin-2 or therapy with high-dose interleukin-2 alone in 157 patients with metastatic cancer for whom standard therapy had proved ineffective or no standard effective treatment was available. One hundred eight patients were treated with 127 courses of LAK cells plus interleukin-2, and 49 patients were treated with 53 courses of high-dose interleukin-2 alone. Of 106 evaluable patients receiving LAK cells plus interleukin-2, 8 had complete responses, 15 had partial responses, and 10 had minor responses. The median duration of response was 10 months among those with complete responses and 6 months among those with partial responses; the patient with the longest complete response was still in remission 22 months after treatment. Of 46 evaluable patients treated with high-dose interleukin-2 alone, 1 had a complete response (remission greater than 4 months), 5 had partial responses (2, greater than 3, greater than 5, 7, and greater than 11 months), and 1 had a minor response. Seven of the total of nine complete responses still remain in remission. Hypotension, weight gain, oliguria, and elevation of bilirubin and creatinine levels were common, but these side effects resolved promptly after interleukin-2 administration was stopped. There have been four treatment-related deaths among these 157 patients. This immunotherapeutic approach can result in marked tumor regression in some patients for whom no other effective therapy is available at present. Determining its ultimate role in cancer therapy awaits further attempts to increase the therapeutic efficacy of treatment and decrease its toxicity and complexity.</AbstractText></Abstract><AuthorList CompleteYN="N"><Author ValidYN="Y"><LastName>Rosenberg</LastName><ForeName>S A</ForeName><Initials>SA</Initials></Author><Author ValidYN="Y"><LastName>Lotze</LastName><ForeName>M T</ForeName><Initials>MT</Initials></Author><Author ValidYN="Y"><LastName>Muul</LastName><ForeName>L M</ForeName><Initials>LM</Initials></Author><Author ValidYN="Y"><LastName>Chang</LastName><ForeName>A E</ForeName><Initials>AE</Initials></Author><Author ValidYN="Y"><LastName>Avis</LastName><ForeName>F P</ForeName><Initials>FP</Initials></Author><Author ValidYN="Y"><LastName>Leitman</LastName><ForeName>S</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Linehan</LastName><ForeName>W M</ForeName><Initials>WM</Initials></Author><Author ValidYN="Y"><LastName>Robertson</LastName><ForeName>C N</ForeName><Initials>CN</Initials></Author><Author ValidYN="Y"><LastName>Lee</LastName><ForeName>R E</ForeName><Initials>RE</Initials></Author><Author ValidYN="Y"><LastName>Rubin</LastName><ForeName>J T</ForeName><Initials>JT</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>N Engl J Med</MedlineTA><NlmUniqueID>0255562</NlmUniqueID><ISSNLinking>0028-4793</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007376">Interleukin-2</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011994">Recombinant Proteins</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002648" MajorTopicYN="N">Child</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003131" MajorTopicYN="N">Combined Modality Therapy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005069" MajorTopicYN="N">Evaluation Studies as Topic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007116" MajorTopicYN="N">Immunization, Passive</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007167" MajorTopicYN="N">Immunotherapy</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007376" MajorTopicYN="N">Interleukin-2</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="Y">administration &amp; dosage</QualifierName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007694" MajorTopicYN="N">Killer Cells, Natural</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007937" MajorTopicYN="N">Leukapheresis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008213" MajorTopicYN="N">Lymphocyte Activation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009369" MajorTopicYN="N">Neoplasms</DescriptorName><QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011994" MajorTopicYN="N">Recombinant Proteins</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>1987</Year><Month>4</Month><Day>9</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>1987</Year><Month>4</Month><Day>9</Day><Hour>0</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>1987</Year><Month>4</Month><Day>9</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">3493432</ArticleId><ArticleId IdType="doi">10.1056/NEJM198704093161501</ArticleId></ArticleIdList></PubmedData></PubmedArticle></PubmedArticleSet>
